Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. until September 2024, where he managed its healthcare public and […]
Team Role: Leadership
Samir Vattompadam, MS
Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional program strategy teams, including external partners, for lead candidates in immuno-oncology […]
David Phillips, MBA
David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He […]
Eyal Attar, MD
Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as senior vice president and CMO for Aprea Therapeutics where he led development […]
Tania Philipp
Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company […]
Tirtha Chakraborty, PhD
Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on […]
John King, MBA
John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global […]
Robert Ang, MBBS, MBA
Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested […]